Xeris Enters Into an Exclusive Worldwide Collaboration and License Agreement with Beta Bionics [Yahoo! Finance]
Xeris Biopharma Holdings, Inc. (XERS)
Last xeris biopharma holdings, inc. earnings: 3/11 06:00 am
Check Earnings Report
Company Research
Source: Yahoo! Finance
CHICAGO, May 06, 2024 BUSINESS WIRE )--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that it has entered into an exclusive worldwide collaboration and license agreement with Beta Bionics, Inc. for the development and commercialization of a glucagon product utilizing Xeris' XeriSol™ technology for use in Beta Bionics' proprietary bi-hormonal pump and pump systems. "We're excited to be partnering with Beta Bionics by being the exclusive provider of the glucagon component that will facilitate their development of the first dual-hormone pump for people with diabetes," said Paul R. Edick, Chairman and CEO of Xeris. "We will move quickly to support Beta Bionics in this important development program." "If insulin is like the gas pedal in your car, then glucagon is the brakes," said Sean Saint, CEO of Beta Bio
Show less
Read more
Impact Snapshot
Event Time:
XERS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
XERS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
XERS alerts
High impacting Xeris Biopharma Holdings, Inc. news events
Weekly update
A roundup of the hottest topics
XERS
News
- Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Q1 2024 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
- Xeris Biopharma Holdings, Inc. (NASDAQ: XERS) had its "overweight" rating re-affirmed by analysts at Piper Sandler. They now have a $3.00 price target on the stock, down previously from $4.00.MarketBeat
- Xeris Biopharma Reports First Quarter 2024 Financial Results and Recent Events [Yahoo! Finance]Yahoo! Finance
- Xeris Biopharma Reports First Quarter 2024 Financial Results and Recent EventsBusiness Wire
- Xeris Enters Into an Exclusive Worldwide Collaboration and License Agreement With Beta BionicsAccesswire
XERS
Earnings
- 5/9/24 - Miss
XERS
Sec Filings
- 5/10/24 - Form 4
- 5/9/24 - Form 10-Q
- 5/9/24 - Form 8-K
- XERS's page on the SEC website